The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
Rook
A H
AH
Department of Dermatology, University of Pennsylvania, Philadelphia 19104, USA. arook@mail.med.upenn.edu
Zaki
M H
MH
Wysocka
M
M
Wood
G S
GS
Duvic
M
M
Showe
L C
LC
Foss
F
F
Shapiro
M
M
Kuzel
T M
TM
Olsen
E A
EA
Vonderheid
E C
EC
Laliberte
R
R
Sherman
M L
ML
D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D018664:Interleukin-12 / Q000009:adverse effects / Q000627:therapeutic use*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000145:classification; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D016896:Treatment Outcome
D000945:Antigens, Differentiation, T-Lymphocyte; D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D018664:Interleukin-12